{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:29:00Z","timestamp":1767677340460,"version":"3.48.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Advanced base-of-tongue squamous cell carcinoma (BOT-SCC) has conventionally been regarded as unsuitable for transoral resection owing to its propensity for deep invasion and the difficulty in obtaining adequate surgical margins. We evaluated whether neoadjuvant therapy could enable transoral robotic surgery (TORS) in a subset of patients with advanced BOT-SCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective analysis, nine consecutive patients with stage \u2265T4N2bM0 BOT-SCC received three cycles of neoadjuvant therapy based on pembrolizumab, followed by TORS with concurrent neck dissection. Radiologic response and tumor shrinkage were assessed after neoadjuvant therapy. Perioperative outcomes, correlations between radiologic shrinkage and operative metrics, postoperative complications (Clavien -Dindo), and 3-month functional outcomes (MD Anderson Dysphagia Inventory [MDADI], Functional Oral Intake Scale [FOIS], and Grade, Roughness, Breathiness, Asthenia, Strain [GRBAS]) were recorded. Follow-up was conducted for oncologic outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Post-neoadjuvant radiologic evaluation demonstrated clinically meaningful downstaging, with partial response in 6\/9 patients (66.7%) and stable disease in 3\/9 patients (33.3%). Mean tumor reduction was 35.6% \u00b1 11.2% (median, 36%; interquartile range [IQR], 28 -44). All patients achieved R0 resection. Mean operative time was 193.3 \u00b1 46.9 min (median, 180; IQR, 165 -240), and mean intraoperative blood loss was 78.3 \u00b1 25.4 mL (median, 70; IQR, 60 -100). Tumor shrinkage was inversely correlated with operative time (r = \u22120.962; 95% CI: \u22120.992 to \u22120.825; p &amp;lt; 0.001) and blood loss (r = \u22120.851; 95% CI: \u22120.968 to \u22120.430; p = 0.004), while operative time was positively correlated with blood loss (r = 0.864; 95% CI: 0.469 to 0.971; p = 0.003). No Clavien -Dindo grade \u2265III complications or postoperative hemorrhage occurred. At 3 months, functional outcomes were favorable (mean MDADI 75.6 \u00b1 10.2; FOIS \u22656 in 55.6%; median GRBAS 1.1). Over a median follow-up of 12 months, no local recurrences or distant metastases were documented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Neoadjuvant therapy may render a subset of patients with advanced BOT-SCC eligible for TORS, enabling oncologically radical resection with low perioperative morbidity and promising early functional recovery. Prospective studies are warranted to validate patient selection criteria and to develop biomarker-guided de-intensification strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1709974","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:19:03Z","timestamp":1767676743000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Conversion TORS after neoadjuvant immunotherapy for advanced BOT-SCC: a retrospective study"],"prefix":"10.3389","volume":"15","author":[{"given":"Quanquan","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinlong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuli","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yipeng","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boning","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haizhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Xi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare12101014","article-title":"Role of TORS as de-escalation strategy in HPV-related OPC: what we need to know","volume":"12","author":"Molteni","year":"2024","journal-title":"Healthcare (Basel)"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-84539-0_17","article-title":"Is reducing the extent of local treatments justified after successful neoadjuvant therapy","volume-title":"Critical Issues in Head and Neck Oncology","author":"Dietz","year":"2025"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.12.8562","article-title":"PET\/CT deformable registration before\/after chemotherapy for RT planning in HNC","volume":"199","author":"Schoenfeld","year":"2012","journal-title":"AJR Am J Roentgenol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/annonc\/mdh001","article-title":"Is there still a role for neoadjuvant chemotherapy in head and neck cancer","volume":"15","author":"Licitra","year":"2004","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy\u2026 (KEYNOTE-048)","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02275-x","article-title":"Pembrolizumab + cabozantinib in RM-HNSCC: phase 2","volume":"29","author":"Saba","year":"2023","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1038\/s41467-024-46444-z","article-title":"Neoadjuvant camrelizumab + nab-paclitaxel + cisplatin in resectable LA-HNSCC: pilot phase II","volume":"15","author":"Wu","year":"2024","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2022.09.017","article-title":"A tactical nanomissile mobilizing antitumor immunity enables neoadjuvant chemo-immunotherapy","volume":"13","author":"He","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21388","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.31","article-title":"p16 immunohistochemistry in oropharyngeal squamous cell carcinoma: a comparison of antibody clones using patient outcomes and high-risk human papillomavirus RNA status","volume":"30","author":"Shelton","year":"2017","journal-title":"Modern pathology: an Off J United States Can Acad Pathology Inc"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1695","article-title":"Neoadjuvant and adjuvant pembrolizumab in resectable LA, HPV-unrelated HNSCC: multicenter phase II","volume":"26","author":"Uppaluri","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.05.005","article-title":"A Hard Truth to Swallow: Critically Evaluating the MD Anderson Dysphagia Inventory (MDADI) as an Endpoint in Human Papillomavirus-associated Oropharyngeal Cancer Trials","volume":"120","author":"McDowell","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2023.05.023","article-title":"Effect of cerebellar TMS","volume":"16","author":"Dai","year":"2023","journal-title":"Brain Stimul"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/hed.25332","article-title":"Transoral robotic-assisted supracricoid partial laryngectomy with cricohyoidoepiglottopexy","volume":"40","author":"Morisod","year":"2018","journal-title":"Head Neck"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2024.108434","article-title":"QoL comparing primary TORS vs radiotherapy for early OPSCC: systematic review and meta-analysis","volume":"50","author":"Gupta","year":"2024","journal-title":"Eur J Surg Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-025-09537-z","article-title":"Quality of life (QoL) following transoral robotic surgery (TORS) resection of parapharyngeal space tumours","volume":"282","author":"Gupta","year":"2025","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2955","article-title":"Neoadjuvant nivolumab \u00b1 ipilimumab in untreated oral cavity SCC: phase 2 RCT","volume":"6","author":"Schoenfeld","year":"2020","journal-title":"JAMA Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e161400","DOI":"10.1172\/JCI161400","article-title":"Enhanced neoepitope-specific immunity after neoadjuvant PD-L1 + TGF-\u03b2 blockade in HPV-unrelated HNSCC","volume":"132","author":"Redman","year":"2022","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7150\/jca.27199","article-title":"PD-1\/PD-L1 expression predicts radiosensitivity","volume":"10","author":"Lyu","year":"2019","journal-title":"J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1596583","article-title":"Advances and challenges in immunotherapy in head and neck cancer","volume":"16","author":"Aboaid","year":"2025","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Pembrolizumab in RM-HNSCC (KEYNOTE-012): phase 1b","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00121","article-title":"The feasibility and safety of surgery in patients receiving immune checkpoint inhibitors","volume":"7","author":"Elias","year":"2017","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors in oncogenic-driver lung cancer: IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2024.0350","article-title":"Preoperative circulating tumor HPV DNA and oropharyngeal squamous cell disease","volume":"150","author":"Lam","year":"2024","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-014-2985-7","article-title":"Functional outcomes after TORS for oropharyngeal cancer: a systematic review","volume":"272","author":"Hutcheson","year":"2015","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29938","article-title":"Increase in primary surgical treatment of T1 and T2 oropharyngeal SCC","volume":"122","author":"Cracchiolo","year":"2016","journal-title":"Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.105798","article-title":"A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers","volume":"127","author":"Brody","year":"2022","journal-title":"Oral Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2021.105307","article-title":"Oncologic and survival outcomes for resectable LA HPV-related OPC treated with TORS","volume":"118","author":"Yver","year":"2021","journal-title":"Oral Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12102337","article-title":"Neoadjuvant immunotherapy in head and neck cancers: a paradigm shift","volume":"12","author":"Zotta","year":"2024","journal-title":"Biomedicines"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyad168","article-title":"TORS in Japan: procedures, advantages and status","volume":"54","author":"Sano","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5434","article-title":"Biomarkers predictive of response to pembrolizumab in HNSCC","volume":"12","author":"Pfister","year":"2023","journal-title":"Cancer Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2015\/12191.6671","article-title":"Induction chemotherapy with cisplatin and 5-fluorouracil in advanced HNSCC: short-term response","volume":"9","author":"Rao","year":"2015","journal-title":"J Clin Diagn Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/nu17172838","article-title":"Protective Role of Key Micronutrients in Chemotherapy-Induced Organ Toxicity: A Comprehensive Review of Mechanistic Insights and Clinical Implications","volume":"17","author":"Konstantinidis","year":"2025","journal-title":"Nutrients"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1709974\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:19:04Z","timestamp":1767676744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1709974\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":35,"alternative-id":["10.3389\/fonc.2025.1709974"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1709974","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"article-number":"1709974"}}